Literature DB >> 26215868

A TPL2 (MAP3K8) disease-risk polymorphism increases TPL2 expression thereby leading to increased pattern recognition receptor-initiated caspase-1 and caspase-8 activation, signalling and cytokine secretion.

Matija Hedl1, Clara Abraham1.   

Abstract

OBJECTIVE: IBD is characterised by dysregulated intestinal immune homeostasis and cytokine secretion. In the intestine, properly regulating pattern recognition receptor (PRR)-mediated signalling and cytokines is crucial given the ongoing host-microbial interactions. TPL2 (MAP3K8, COT) contributes to PRR-initiated pathways, yet the mechanisms for TPL2 signalling contributions in primary human myeloid cells are incompletely understood and its role in intestinal myeloid cells is poorly defined. Furthermore, functional consequences for the IBD-risk locus rs1042058 in TPL2 are unknown.
METHODS: We analysed protein, cytokine and RNA expression, and signalling in human monocyte-derived macrophages (MDMs) through western blot, ELISA, real-time PCR and flow cytometry.
RESULTS: PRR-induced cytokine secretion was increased in MDMs from rs1042058 TPL2 GG risk individuals. TPL2 activation by the Crohn's disease-associated PRR nucleotide-oligomerisation domain (NOD)2 required PKC, and IKKβ, IKKα and IKKγ signalling. TPL2, in turn, significantly enhanced NOD2-induced ERKJNK and NFκB signalling. We found that another major mechanism for the TPL2 contribution to NOD2 signalling was through ERK-dependent and JNK-dependent caspase-1 and caspase-8 activation, which in turn, led to early autocrine interleukin (IL)-1β and IL-18 secretion and amplification of long-term cytokines. Importantly, Salmonella typhimurium-induced cytokines from human intestinal myeloid-derived cells required TPL2 as well as autocrine IL-1β and IL-18. Finally, rs1042058 GG risk carrier MDMs from healthy individuals and patients with Crohn's disease had increased TPL2 expression and NOD2-initiated TPL2 phosphorylation, ERK, JNK and NFκB activation, and early autocrine IL-1β and IL-18 secretion.
CONCLUSIONS: Taken together, the rs1042058 GG IBD-risk polymorphism in TPL2 results in a gain-of-function by increasing TPL2 expression and signalling, thereby amplifying PRR-initiated outcomes. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  IBD BASIC RESEARCH; IMMUNOLOGY; MACROPHAGES

Mesh:

Substances:

Year:  2015        PMID: 26215868      PMCID: PMC5106344          DOI: 10.1136/gutjnl-2014-308922

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  48 in total

1.  Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract.

Authors:  Koichi S Kobayashi; Mathias Chamaillard; Yasunori Ogura; Octavian Henegariu; Naohiro Inohara; Gabriel Nuñez; Richard A Flavell
Journal:  Science       Date:  2005-02-04       Impact factor: 47.728

2.  Tpl2 (tumor progression locus 2) phosphorylation at Thr290 is induced by lipopolysaccharide via an Ikappa-B Kinase-beta-dependent pathway and is required for Tpl2 activation by external signals.

Authors:  Jeonghee Cho; Michael Melnick; Georgios P Solidakis; Philip N Tsichlis
Journal:  J Biol Chem       Date:  2005-03-18       Impact factor: 5.157

3.  Transformation of mammalian cells by constitutively active MAP kinase kinase.

Authors:  S J Mansour; W T Matten; A S Hermann; J M Candia; S Rong; K Fukasawa; G F Vande Woude; N G Ahn
Journal:  Science       Date:  1994-08-12       Impact factor: 47.728

4.  Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: a potential target for the treatment of Crohn's disease?

Authors:  M Lawrenz; A Visekruna; A Kühl; N Schmidt; S H E Kaufmann; U Steinhoff
Journal:  Mucosal Immunol       Date:  2011-12-07       Impact factor: 7.313

5.  Macrophage stimulation with Murabutide, an HIV-suppressive muramyl peptide derivative, selectively activates extracellular signal-regulated kinases 1 and 2, C/EBPbeta and STAT1: role of CD14 and Toll-like receptors 2 and 4.

Authors:  V F Vidal; N Castéran; C J Riendeau; H Kornfeld; E C Darcissac; A Capron; G M Bahr
Journal:  Eur J Immunol       Date:  2001-07       Impact factor: 5.532

6.  Role of nod2 in the response of macrophages to toll-like receptor agonists.

Authors:  Anne-Laure Pauleau; Peter J Murray
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

7.  Genomic responses in mouse models poorly mimic human inflammatory diseases.

Authors:  Junhee Seok; H Shaw Warren; Alex G Cuenca; Michael N Mindrinos; Henry V Baker; Weihong Xu; Daniel R Richards; Grace P McDonald-Smith; Hong Gao; Laura Hennessy; Celeste C Finnerty; Cecilia M López; Shari Honari; Ernest E Moore; Joseph P Minei; Joseph Cuschieri; Paul E Bankey; Jeffrey L Johnson; Jason Sperry; Avery B Nathens; Timothy R Billiar; Michael A West; Marc G Jeschke; Matthew B Klein; Richard L Gamelli; Nicole S Gibran; Bernard H Brownstein; Carol Miller-Graziano; Steve E Calvano; Philip H Mason; J Perren Cobb; Laurence G Rahme; Stephen F Lowry; Ronald V Maier; Lyle L Moldawer; David N Herndon; Ronald W Davis; Wenzhong Xiao; Ronald G Tompkins
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-11       Impact factor: 11.205

8.  Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection.

Authors:  Stephen E Girardin; Ivo G Boneca; Jérôme Viala; Mathias Chamaillard; Agnès Labigne; Gilles Thomas; Dana J Philpott; Philippe J Sansonetti
Journal:  J Biol Chem       Date:  2003-01-13       Impact factor: 5.157

9.  Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis.

Authors:  Tomohiro Watanabe; Naoki Asano; Peter J Murray; Keiko Ozato; Prafullakumar Tailor; Ivan J Fuss; Atsushi Kitani; Warren Strober
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

10.  Protein kinase IKKβ-catalyzed phosphorylation of IRF5 at Ser462 induces its dimerization and nuclear translocation in myeloid cells.

Authors:  Marta Lopez-Pelaez; Douglas J Lamont; Mark Peggie; Natalia Shpiro; Nathanael S Gray; Philip Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-17       Impact factor: 11.205

View more
  13 in total

Review 1.  From sensing to shaping microbiota: insights into the role of NOD2 in intestinal homeostasis and progression of Crohn's disease.

Authors:  Iyshwarya Balasubramanian; Nan Gao
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-04-27       Impact factor: 4.052

2.  IL23 induces IL23R recycling and amplifies innate receptor-induced signalling and cytokines in human macrophages, and the IBD-protective IL23R R381Q variant modulates these outcomes.

Authors:  Rui Sun; Matija Hedl; Clara Abraham
Journal:  Gut       Date:  2019-05-16       Impact factor: 23.059

Review 3.  Pattern Recognition Receptor Signaling and Cytokine Networks in Microbial Defenses and Regulation of Intestinal Barriers: Implications for Inflammatory Bowel Disease.

Authors:  Clara Abraham; Maria T Abreu; Jerrold R Turner
Journal:  Gastroenterology       Date:  2022-02-09       Impact factor: 33.883

4.  An inflammatory bowel disease-risk variant in INAVA decreases pattern recognition receptor-induced outcomes.

Authors:  Jie Yan; Matija Hedl; Clara Abraham
Journal:  J Clin Invest       Date:  2017-04-24       Impact factor: 14.808

5.  ABIN2 Function Is Required To Suppress DSS-Induced Colitis by a Tpl2-Independent Mechanism.

Authors:  Sambit K Nanda; Tsunehisa Nagamori; Mark Windheim; Sylvia Amu; Gabriella Aviello; Janet Patterson-Kane; J Simon C Arthur; Steven C Ley; Padraic Fallon; Philip Cohen
Journal:  J Immunol       Date:  2018-10-24       Impact factor: 5.422

Review 6.  Tumor progression locus 2 (TPL2) in tumor-promoting Inflammation, Tumorigenesis and Tumor Immunity.

Authors:  Lucy Wanjiru Njunge; Andreanne Poppy Estania; Yao Guo; Wanqian Liu; Li Yang
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

7.  Tpl2 Protects Against Fulminant Hepatitis Through Mobilization of Myeloid-Derived Suppressor Cells.

Authors:  Jing Xu; Siyu Pei; Yan Wang; Junli Liu; Youcun Qian; Mingzhu Huang; Yanyun Zhang; Yichuan Xiao
Journal:  Front Immunol       Date:  2019-08-20       Impact factor: 7.561

8.  Foot-and-Mouth Disease Virus Capsid Protein VP1 Antagonizes TPL2-Mediated Activation of the IRF3/IFN-β Signaling Pathway to Facilitate the Virus Replication.

Authors:  Junhong Hao; Chaochao Shen; Nannan Wei; Minghao Yan; Xuegang Zhang; Guowei Xu; Dajun Zhang; Jing Hou; Weijun Cao; Ye Jin; Keshan Zhang; Haixue Zheng; Xiangtao Liu
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

9.  Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles.

Authors:  Erik Andersson; Daniel Bergemalm; Robert Kruse; Gunter Neumann; Mauro D'Amato; Dirk Repsilber; Jonas Halfvarson
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

Review 10.  The Role of NLRP3 and IL-1β in the Pathogenesis of Inflammatory Bowel Disease.

Authors:  Liming Mao; Atsushi Kitani; Warren Strober; Ivan J Fuss
Journal:  Front Immunol       Date:  2018-11-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.